An influence of Treatment of Renal Anemia on Iron Dysregulation in patients with chronic kidney disease

An influence of Treatment of Renal Anemia on Iron Dysregulation in patients with chronic kidney disease - TRAID study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004136

Enrollment

Registered

2010-09-01

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease (CKD)

Interventions

EPO is changed to darbepoietin as treatment of renal anemia darbepoietin as treatment of renal anemia no intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemodialysis patients with Hb <10 g/dl, serum feritin >200ng/ml

Exclusion criteria

Exclusion criteria: malignant disease, blood disease, severe infection

Design outcomes

Secondary

Measure	Time frame
inflammation and oxidative stress: high-sensitivity-CRP,pentraxin,inflammatory cytokines (IL-6,TNF-alpha), malondialdehyde,8-OHdG etc. MBD: metabolism of Ca and P (PTH,FGF23,fetuinA),markers of bone metabolism (BMD etc.),markers of vasculopathy (pulse wave velocity etc.)	—

Primary

Measure	Time frame
Anemia: RBC,Hb,Ht,reticulocytes etc. Iron metabolism: serum iron, TIBC, Tsat, ferritin,hepcidin,aminolevulinic acid,iron transporters etc.	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Division fo Kidney and Dialysis, Department of Internal Medicine

jin@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026